Real-world multicenter study of PD-1 blockade in HIV-associated classical Hodgkin lymphoma across the United States

Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on the use of these agents in HIV-associated cHL (HIV-cHL).

Source: Clinical Lymphoma, Myeloma and Leukemia - April 5, 2024 Category: Hematology Authors: Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E. Drolen, Tatyana Feldman, Tarek Haykal, Caroline A. Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Ki Tags: Original Study Source Type: research